Join to View Full Profile
10903 New Hampshire AveBuilding 22, Room 2328Silver Spring, MD 20903
Phone+1 301-796-1387
Dr. Keegan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University at BuffaloFellowship, Hematology and Medical Oncology, 1982 - 1984
Loyola University Medical CenterResidency, Internal Medicine, 1979 - 1982
Loyola University Chicago Stritch School of MedicineClass of 1979, MD
Certifications & Licensure
MD State Medical License 1991 - 2026
NC State Medical License 1986 - 1992
IL State Medical License 1981 - 1987
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng
Future Oncology. 2025-02-01 - Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study.Aung Naing, Amit Mahipal, Milind Javle, Judy Wang, Todd M Bauer
Journal of Immunotherapy and Precision Oncology. 2025-02-01 - A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC).Zhijie Wang, Lin Wu, Baolan Li, Ying Cheng, Xiaoling Li
Future Oncology. 2025-02-01
Press Mentions
Junshi Biosciences Announces Submission of a Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory AgencyNovember 24th, 2022- Junshi Biosciences Announces Submission of a Marketing Authorization Application to the European Medicines Agency for ToripalimabNovember 15th, 2022
- Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary SeriesMarch 15th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
